オプションチェーンは、Ocugenの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Ocugenの市場センチメントを評価します。.

Ocugen (NASDAQ:OCGN) 株価情報, オプションチェーン

OCUGEN INC

Ocugen

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

Ocugen Inc

UBS analyst Timothy Chiodo maintains Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) with a Neutral and lowers the price target from $7.5 to $4.5.

News

Price Target

Analyst Ratings

RPAY

UBS Maintains Neutral on Repay Holdings, Lowers Price Target to $4.5

Earnings results this week spanned several sectors represented in Dan Loeb's Third Point portfolio, offering new insight into the <a href="https://www.benzinga.com/earnings">firm&#8217;s Q4 2024 positions.</a>
Cinemark Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>): The investor reduced its stake from 7,000,000 shares <a href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624005927/xslForm13F_X02/infotable.xml" target="_blank" rel="noreferrer noopener">in </a>the third quarter of 2024 to 3,750,000 shares <a href="https://www.sec.gov/Archives/edgar/data/1040273/000108514625001713/xslForm13F_X02/infotable.xml" target="_blank" rel="noreferrer noopener">in </a>the fourth quarter of 2024.
<ul class="wp-block-list">
<li>The company registered&nbsp;first-quarter EPS losses of 32 cents, compared with the analyst consensus estimate of 10 cents loss and sales of&nbsp;$540.70 million&nbsp;(down&nbsp;6.6%&nbsp;year over year) outpaced the <a href="https://www.benzinga.com//node/45169195" target="_blank" rel="noreferrer noopener">street view of&nbsp;$540.68 million</a>.</li>
<li>JP Morgan analyst David Karnovsky writes that compared to their forecast of $515 million in revenue and $26 million in EBITDA, the outperformance was driven across key metrics, including higher attendance, improved per-patron spending, <a href="https://www.benzinga.com//node/45209210" target="_blank" rel="noreferrer noopener">and additional revenue streams</a>.</li>
<li>D-Box technologies announced expansion of its relationship with Cinemark and will add over 70 D-box haptic-enabled screens across as many as 25 Cinemark theaters in the United<a href="https://www.benzinga.com//node/45282827"> States in the next eighteen months</a>.</li>
<li>Year to date, Cinemark fell about 2.13%, compared to the Invesco S&amp;P SmallCap Utilities &amp; Communication Services ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSCU#NASDAQ">PSCU</a>), which declined about 5.73%&nbsp;over the same time frame.</li>
</ul>
Corpay, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>): Third Point had trimmed its stake from 765,000 shares in the&nbsp;third quarter&nbsp;of 2024 to 610,000 shares in&nbsp;the&nbsp;fourth quarter&nbsp;of 2024.
<ul class="wp-block-list">
<li>The company reported first quarter adjusted EPS of&nbsp;$4.51, in line with the consensus, and sales of&nbsp;$1.01 billion<a href="https://www.benzinga.com//node/45238012" target="_blank" rel="noreferrer noopener">, missing the street view of&nbsp;$1.02 billion</a>.</li>
<li>Corpay slightly narrowed its 2025 adjusted EPS guidance to $20.80 to $21.20 (from $20.75 to $21.25 prior) vs. <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">consensus estimate of $21.08</a>.</li>
<li>The company has increased its 2025 sales guidance to $4.38 billion to $4.46 billion (from its prior range of $4.35 billion to $4.45 billion) vs. the analyst consensus estimate of $4.40 billion.</li>
<li>UBS analyst Roger Boyd lowered the price forecast from $400 to $365, and Raymond James analyst slashed the price <a href="https://www.benzinga.com/quote/cpay/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast from $417 to $414</a>.</li>
<li>AvidXchange Holdings, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) inked a deal to be acquired&nbsp;by&nbsp;Corpay and&nbsp;TPG Inc.&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/TPG#NASDAQ" target="_blank" rel="noreferrer noopener"> TPG</a>) for $10&nbsp;per share in cash, <a href="https://www.benzinga.com//node/45250388" target="_blank" rel="noreferrer noopener">valuing the company at&nbsp;$2.2 billion</a>.</li>
<li>Year to date, Corpay rose about 3.32%, almost similar to SMI 3Fourteen Full-Cycle Trend ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCTE#NASDAQ">FCTE</a>), which rose about 3.16%&nbsp;over the same time frame.</li>
</ul>
Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>):&nbsp;Loeb had 1,650,000 shares in the company&nbsp;as of the fourth quarter of 2024.
<ul class="wp-block-list">
<li>The company reported&nbsp;a second-quarter&nbsp;2025&nbsp;revenue increase of 2.2%&nbsp;year-over-year to&nbsp;$2.91 billion, topping the&nbsp;$2.18 billion&nbsp;consensus and adjusted EPS of $1.43, which came <a href="https://www.benzinga.com//node/45229501" target="_blank" rel="noreferrer noopener">above the consensus of&nbsp;$1.39</a>.</li>
<li>Jacobs sees adjusted net revenue growing mid-to-high single digits, with an EBITDA margin of&nbsp;13.8-14.0%&nbsp;and FCF conversion exceeding&nbsp;100%&nbsp;of net income.</li>
<li>The company expects adjusted EPS of&nbsp;$5.85&nbsp;–&nbsp;$6.20&nbsp;(versus the&nbsp;$6.03&nbsp;consensus) for 2025.</li>
<li>RBC Capital analyst Sabahat Khan raised the price forecast from&nbsp;$152&nbsp;to&nbsp;$154, Truist Securities analyst Jamie Cook boosted the price forecast from&nbsp;$130&nbsp;to&nbsp;$141, while UBS analyst Steven Fisher lowered <a href="https://www.benzinga.com/quote/J/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast from&nbsp;$154&nbsp;to&nbsp;$152</a>.</li>
<li>Year to date, the company&#8217;s share declined about 4.57% vs. Valued Advisers Trust Kovitz Core Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQTY#NYSE">EQTY</a>), which rose about 0.04%&nbsp;over the same time frame.</li>
</ul>
Primo Brands Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRMB#NYSE">PRMB</a>): The investor acquired a stake in the company, attaining 2,400,000 shares&nbsp;in the fourth quarter 2024.
<ul class="wp-block-list">
<li>The company&nbsp;reported&nbsp;first-quarter&nbsp;revenue growth of&nbsp;42.1%&nbsp;year-on-year to&nbsp;$1.61 billion, missing the analyst consensus estimate of&nbsp;$1.62 billion, while adjusted EPS of 29 cents&nbsp;beat the <a href="https://www.benzinga.com//node/45292629" target="_blank" rel="noreferrer noopener">consensus&nbsp;estimate of 23 cents</a>.</li>
<li>&nbsp;For 2025, Primo sees net sales growth of&nbsp;3%–5% and expects <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">adjusted EBITDA of&nbsp;$1.6 billion–$1.628 billion</a>.</li>
<li>Mizuho analyst John Baumgartner initiated coverage on with an Outperform rating <a href="https://www.benzinga.com/quote/prmb/analyst-ratings" target="_blank" rel="noreferrer noopener">and a price forecast of&nbsp;$43</a>.</li>
<li>Year to date, Primo Brands increased about 3.35%, compared to Global X Clean Water ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQWA#NASDAQ">AQWA</a>), which rose about 7.49%&nbsp;over the same time frame.</li>
</ul>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45234285/amazon-meta-microsoft-earnings-put-dan-loebs-portfolio-to-the-test" target="_blank" rel="noreferrer noopener">Amazon, Meta, Microsoft Earnings Put Dan Loeb&#8217;s Portfolio To The Test</a></li>
</ul>
Photo: Shutterstock

Large Cap

Mid Cap

AQWA

AVDX

CPAY

EQTY

FCTE

PRMB

PSCU

Earnings Just Put Dan Loeb's Bets To The Test — Here's What Held Up

Piper Sandler analyst Mark Lear maintains Sitio Royalties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STR#NYSE">STR</a>) with a Overweight and lowers the price target from $28 to $26.

Piper Sandler Maintains Overweight on Sitio Royalties, Lowers Price Target to $26

UBS analyst Damian Karas maintains Crane NXT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXT#NYSE">CXT</a>) with a Neutral and lowers the price target from $62 to $60.

UBS Maintains Neutral on Crane NXT, Lowers Price Target to $60

Piper Sandler analyst Mark Lear maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Neutral and raises the price target from $32 to $40.

Piper Sandler Maintains Neutral on Range Resources, Raises Price Target to $40

Piper Sandler analyst Mark Lear maintains Prairie Operating (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROP#NASDAQ">PROP</a>) with a Overweight and lowers the price target from $11 to $10.

PROP

Piper Sandler Maintains Overweight on Prairie Operating, Lowers Price Target to $10

UBS analyst Jon Windham maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Neutral and raises the price target from $4.5 to $6.

FLNC

UBS Maintains Neutral on Fluence Energy, Raises Price Target to $6

Piper Sandler analyst Mark Lear maintains Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>) with a Overweight and lowers the price target from $20 to $19.

Piper Sandler Maintains Overweight on Permian Resources, Lowers Price Target to $19

Macro Economic Events

WIIM

Economics

Major indexes are higher following softer-than-expected April inflation readings. Additionally, investors continue to weigh US-China trade progress and President Trump's Middle East trip.

SPDR Dow Jones Industrial Average ETF Trust

The Dow is lower amid weakness in one of its largest components, UnitedHealth, which fell after announcing a CEO change and suspending guidance.

Piper Sandler analyst Mark Lear maintains Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) with a Neutral and lowers the price target from $34 to $30.

Piper Sandler Maintains Neutral on Northern Oil & Gas, Lowers Price Target to $30

UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) with a Neutral and lowers the price target from $6 to $5.25.

GDRX

UBS Maintains Neutral on GoodRx Holdings, Lowers Price Target to $5.25

Piper Sandler analyst Mark Lear maintains Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) with a Overweight and lowers the price target from $35 to $30.

Piper Sandler Maintains Overweight on Murphy Oil, Lowers Price Target to $30

Piper Sandler analyst Mark Lear maintains Magnolia Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) with a Neutral and lowers the price target from $25 to $24.

Piper Sandler Maintains Neutral on Magnolia Oil & Gas, Lowers Price Target to $24

VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) reported quarterly earnings of $54.74 per share. This is a 72.67 percent decrease over earnings of $200.28 per share from the same period last year. The company reported $27.82 million in sales this quarter. This is a 40.64 percent increase over sales of $19.79 million the same period last year.

Earnings

VCIG

VCI Global FY EPS $54.74 Down From $200.28 YoY, Sales $27.82M Up From $19.79M YoY

Piper Sandler analyst Mark Lear maintains Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) with a Overweight and lowers the price target from $234 to $225.

FANG

Piper Sandler Maintains Overweight on Diamondback Energy, Lowers Price Target to $225

NuScale Power Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) shares surged 21.4% to $21.60 on Tuesday following the <a href="https://www.benzinga.com/pressreleases/25/05/b45359929/nuscale-power-reports-first-quarter-2025-results">release</a> of its first-quarter earnings after Monday&#8217;s close.
What To Know: The company <a href="https://www.benzinga.com/news/earnings/25/05/45361335/nuscale-power-reports-q1-results-details">reported</a> quarterly revenue of $13.4 million, significantly surpassing analysts&#8217; expectations of $4.26 million. The revenue boost was attributed to progress on its FEED Phase 2 project and a Technology License Agreement for Romania's RoPower Doicești power plant.
NuScale reduced its quarterly operating expenses by $2.3 million year-over-year to $42.3 million, largely due to lower R&amp;D costs as the company advances from development toward commercialization. The company&#8217;s net loss from operations narrowed to $35.3 million from $44.0 million in the same quarter last year.
Read Also: <a href="https://www.benzinga.com/news/25/05/45380609/applovin-stock-surges-on-strong-q1-earnings-and-tariff-truce-tailwinds">AppLovin Stock Surges On Strong Q1 Earnings And Tariff Truce Tailwinds</a>
CEO John Hopkins <a href="https://www.benzinga.com/news/earnings/25/05/45361335/nuscale-power-reports-q1-results-details">emphasized</a> NuScale's ongoing momentum as the only SMR provider with US NRC design approval. He noted that 12 reactor modules are already in production, with a target delivery date set for 2030.
NuScale, along with partner ENTRA1 Energy, is in advanced discussions with a range of potential customers, including governments, data centers and energy firms. 
The company ended the quarter with $521.4 million in liquidity and raised $102.4 million through its ATM equity program, reinforcing its capital position as it scales operations.
Read Also: <a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom">Trump Wants To Kickstart Nuclear Development: These 5 Stocks Could Boom</a>
<h2 class="wp-block-heading">How To Buy SMR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in NuScale Power&#8217;s case, it is in the Industrials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SMR has a 52-week high of $32.30 and a 52-week low of $5.86.

NuScale (SMR) Stock Surges 21% After Smashing Q1 Revenue Estimates

TD Cowen analyst Joseph Thome initiates coverage on Bright Minds Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) with a Buy rating.

Initiation

DRUG

TD Cowen Initiates Coverage On Bright Minds Biosciences with Buy Rating

Piper Sandler analyst Mark Lear maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Neutral and raises the price target from $35 to $48.

Piper Sandler Maintains Neutral on EQT, Raises Price Target to $48

Western Digital shares are trading higher after the company announced a $2 billion buyback program.

Health Care

Press Releases

General

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Legal

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN)

Biotech

Ocugen Announces Positive Opinion of EMA's Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Comments

Ocugen

Ocugen (OCGN) オプション

Ocugen (NASDAQ:OCGN) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル